drop to $45 so I can buy like a fiend... or blast past $50 so my options kick in... We need to fall back or go up by more than $3 a week, week in week out... I am just plain SGEN greedy!!!
If you click on your name this is your post on like 40 stocks... kind of goofy.
The only issue is if it becomes part of a major do they mess it up because they are valued more on current earnings than SGEN. But then you have to be thinking if you are a major player in the cancer space right now you know you won't be 5-7 years from now because the technology is changing so rapidly and SGEN is the future leader. But out of our hands it is whatever the BB have in store for the company.
I agree...totally. Great commentary.
The BBs will make a fortune on the combined SGEN-UNUM relationship...I'm just glad to be tagging along for the ride.
Looking at UNUM and its Antibody-Coupled T-cell Receptor (ACTR) technology, are discovering and developing new cellular immunotherapies for cancer. Their vision is of a single cell therapy that can be applied to the treatment of many different cancers. They recently went into a Series B Financing for $65M. This leads me to believe that what SGEN is seeing is the expanded opportunities based upon Dario Campana's work where he created the CD19 chimeric antigen receptor (CAR) that was subsequently shown to be highly effective in treating patients with ALL, an aggressive form of leukemia. He has extensive experience managing clinical cell therapy trials in oncology. Was this an inexpensive way of controlling the future of ALL treatment? SGEN will make an upfront payment of $25 million and an equity investment of $5 million in Unum’s next round of private financing.
I believe that the real benefit here is the expansion into other areas of cancer. The ACTR technology is a chimeric protein that combines components from receptors normally found on two different human immune cell types – natural killer (NK) cells and T-cells – to create a novel cancer cell killing activity. T-cells bearing the ACTR receptor can be directed to attack tumor cells by providing a monoclonal antibody that binds to antigens on the cancer cell surface and then acts as a bridge to the ACTR T-cell, enabling tumor cell killing. Unum has built a platform for cancer treatment based upon ACTR. In contrast to other approaches that are limited to a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigen and may have applications for treating many types of cancers.
The combination of the SGEN and the UNUM approach should accelerate the rapid expansion of targets. I am willing to bet that the BBs were instrumental in finding and bringing about the deal. This could be the cheapest $30 investment in biotech.
Thanks for sharing your DD results.
This board is the best all around YMB because it is populated with people knowledgeable and with propensity to share their research findings and discuss facts courteously and within the bounds of civility. Don't like to use the word, but in this case it really fits in the most well meaning way; you guys and gals have real class.
From GEVA's 5/22/15 SC 14D9:
Dr. Bell confirmed to Dr. Baker that it was a requirement for Alexion that Dr. Baker agree to be appointed to the Alexion Board following consummation of the transaction between the parties.
Baker Bros held in the highest regards and are a premium for any potential suitor of SGEN.
Same for INCY.
Sentiment: Strong Buy
Excuse the word "puts" as I was attempting to abbreviate patients without realizing spellcheck was changing pts to puts.
I should have mentioned from the start that this was in DLBCL patients.
There were quite a few oral presentations re brentuximab vedotin at this conference. Many from investigator sponsored trials, all of which further confirmed the efficacy of BV and it's use with other treatment options.
You can look up the conference and go to the abstract book and look under the section titled "oral presentations" and find the abstracts.
Updated Adcetris + R CHOP in high intermediate/ high risk patients is very interesting. At ASH in Dec. the initial results were published after 12 puts had been treated. At that time the ORR was 92% with CR of 58%. The ASH paper said a recent study of Rchop alone in that patient group showed a CR rate of 26%. At that point in time the CR rate had more than doubled.
With this most recent update 51 patients have been treated, 62 % high int, 38% high risk. Slightly more high risk than from December. The 1.8 mg Adcetris group was scaled back to 1.2 mg to lessen neuropathy AEs. Of 51 puts treated 30 had EOT assessment.
At EOT of treatment ORR was 97% with CR rate of 80%. In the CD 30+ pts CR rate was 86%. 75% CR rate in CD 30- group. In follow up, none of the CD 30+ puts had progressed, with a median PFS of 5 months. 4 of the 16 CD 30- puts did progress.
Pretty amazing results in this at risk DLBCL group.
Did you read the presentations at the ICML in Lugano? The updates are reflecting why the company keeps moving forward and why BB will invest another chunk of money, although the conference presentations are through the 19th most if not all of the presentations by SGEN were on the 17th and 18th.
Seven oral presentations and one poster at ICML demonstrate the breadth of the clinical development program for ADCETRIS. Data include an additional analysis of the phase 3 AETHERA clinical trial showing that up to 16 cycles (approximately one year) of ADCETRIS consolidation therapy following autologous stem cell transplant (ASCT) significantly extended progression-free survival (PFS) versus placebo for those patients with primary-refractory HL. Another big revenue generator on increased settings and uses.
Institutions and insiders own basically all of the shares outstanding. If I had to venture a guess, the "public" (non-insiders and non-institutions) probably own as little as 10% of the total capitalization, putting what i'd call the "effective float" at around 10-15 million shares (OK 12.6 MM to be precise....which I am not attempting to be).
Because the BBs are the biggest guy in the room and have a strong following, most investors are reluctant to sell, especially since the BBs keep buying. Add to that the recent UNUM deal and most professionals in this stock know that the end game will play out at much higher levels.
You're overthinking it. Enjoy the ride and be happy! All biotechs are up today. In addition SGEN just had major buying by BB and are dipping into immunotherapy. I wouldn't be surprised if we cut through our all time high in the near future.
You must believe that a disclosure and balancing of their June 30th portfolio would dictate the purchase after June 30. Is that what you are thinking MJ? some other BB stocks seem to be getting attention also, so the BBs have some decisions to make in their rebalancing.